Researchers make progress on early detection of resistance to colorectal cancer drugs
Mutations in a gene called KRAS are causally associated with acquired resistance to targeted therapies for colorectal cancers (CRC), according to new findings from EU-funded researchers from Italy and their research colleagues in the United States.
Writing in the journal Nature, the team explain that patients often develop resistance to colorectal cancer drugs that target epidermal growth factor receptors (EGFRs). The team show in cell-line models that KRAS mutations can cause resistance to an anti-EGFR therapy called cetuximab. These mutations can either be acquired during treatment or may have pre-existed in a small fraction of tumour cells before treatment.
Two of the Italian study authors, Professor Alberto Bardelli from the Institute for Cancer Research and Treatment in Turin and Salvatore Siena from the Falck Division of Medical Oncology at the Niguarda Ca' Granda Hospital in Milan, were supported by the EU-funded COLTHERES ('Modelling and predicting sensitivity to targeted therapies in colorectal cancers') project which received EUR 5,999,300 of funding under the 'Health' Theme of the EU's Seventh Framework Programme (FP7).
Professor Bardelli comments: 'Emergence of secondary resistance to anti EGFR therapies (disease progression) in colorectal cancers is presently established by radiological evaluation. In the paper we describe for the first time that KRAS gene alterations are a mechanism of acquired resistance to anti EGFR therapies in CRCs and occur in approximately 50% of patients.'
The findings in this latest study come at the same time as a second team of researchers publish results demonstrating that resistance mutations in KRAS and other genes are highly likely to be present in a subpopulation of tumour cells before treatment. In this complementary study, also published in Nature, researchers from Austria, China and the United States show that these mutations can be detected months before there is clinical evidence of treatment failure, which could provide a signal to start alternative treatments.
These researchers used mathematical modelling to provide evidence that KRAS mutations pre-exist in tumour cells before treatment with the anti-EGFR treatment panitumumab. This may explain why clinical recurrence usually occurs within the same timescale, about 5 to 7 months after treatment began.
Both studies show that DNA from these mutations can be detected in liquid biopsies several months before radiographic evidence of disease progression is observable. The hope now is that scientists will be able to build on these results by using combination therapy to anticipate and counter resistance before patients relapse.
Professor Bardelli explains that both study groups demonstrate that these mutations can be detected in plasma using an approach called 'liquid biopsy'.
He adds: 'This means that it is now possible to monitor the evolution of the tumour in response to therapy using a blood draw to detect early mutations that drive acquired resistance. The concept of liquid biopsy is an important step forward in the field. It was already known that the measurement of circulating tumour free DNA in the blood of patients could be used to monitor tumour burden. Our work shows that molecular determinants of acquired resistance can be detected several months before the clinical manifestation of relapse.'
Professor Bardelli also notes that it is important to clarify that what they have discovered is 'not a novel way to detect colon cancer' rather they have found a strategy to non-invasively detect early relapse from therapy in colorectal cancer patients.
As well as Italy, COLTHERES, which started in 2011 and runs until 2014, supports researchers from Belgium, the Netherlands, Spain, Switzerland and the United Kingdom, and its central aim is to help develop knowledge in the 'personalised' approach to cancer treatment where the 'right' combination of drugs is administered to the 'right' patients, based on a detailed understanding of their genetic background.
Some of the issues the COLTHERES project addresses are molecular profiling of colon cancer patient samples using multiple omics-based technologies for co-segregating lesions that could impart resistance to existing and emerging targeted therapies, and building and screening predictive in vitro models based on this data to enable the rapid and empirical determination of drug resistance biomarkers.
For more information, please visit:
More information: Misale, S., et al. Nature, 2012. doi:10.1038/nature11156
Journal reference: Nature
Provided by CORDIS
- Advanced cancers destined to recur after treatment with single drugs that 'target' tumor cells: study Jun 13, 2012 | not rated yet | 0
- Colorectal cancer patients with gene mutation show better response to cancer agent Oct 26, 2010 | not rated yet | 0
- KRAS gene mutation and amplification status affects sensitivity to antifolate therapy Apr 04, 2012 | not rated yet | 0
- Study identifies a cause of resistance to colon cancer treatment Jan 22, 2012 | not rated yet | 0
- Predicting drug responsiveness in cancer patients Jul 26, 2010 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Pressure-volume curve: Elastic Recoil Pressure don't make sense
12 hours ago From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
Marie Curie's leukemia
May 13, 2013 Does anyone know what might be the cause of Marie Curie's cancer
- More from Physics Forums - Medical Sciences
More news stories
A ground-breaking advance in colonoscopy technology signals the future of colorectal care, according to research presented today at Digestive Disease Week(DDW). Additional research focuses on optimizing the minimal withdrawal ...
Cancer 5 hours ago | 5 / 5 (1) | 0
(HealthDay)—Concurrent use of two immune checkpoint antibodies—ipilimumab and nivolumab—may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in ...
Cancer May 17, 2013 | not rated yet | 0
(HealthDay)—The risks of metastasis and death associated with cutaneous squamous cell carcinoma (CSCC) are low, but significant, and risk factors for poor outcome include tumor diameter, invasion beyond ...
Cancer May 17, 2013 | not rated yet | 0 |
A new review finds cancer survivors suffer a diverse and complex set of impairments, affecting virtually every organ system. Writing in CA: A Cancer Journal for Clinicians, Julie Silver, M.D., associate professor at Harvar ...
Cancer May 17, 2013 | not rated yet | 0
(AP)—A California doctor has been sentenced to 14 years in federal prison for bilking her patients out of more than $1 million by promising that an herbal supplement could cure late-stage cancer and other diseases.
Cancer May 17, 2013 | not rated yet | 0
An increasing number of U.S. children are experiencing gastrointestinal issues that require interventions to resolve, according to research presented at Digestive Disease Week (DDW).
5 hours ago | not rated yet | 0 |
The latest makeover to a massive psychiatric tome honored by some, reviled by others and even called the "Bible" of mental disorders is being released Saturday with a host of new changes.
2 hours ago | not rated yet | 0
A new case of the deadly coronavirus has been detected in Saudi Arabia where 15 people have already died after contracting it, the health ministry announced on Saturday on its Internet website.
3 hours ago | not rated yet | 0
Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.
13 hours ago | 5 / 5 (1) | 0
For combat veterans suffering from post-traumatic stress disorder, 'fear circuitry' in the brain never rests
Chronic trauma can inflict lasting damage to brain regions associated with fear and anxiety. Previous imaging studies of people with post-traumatic stress disorder, or PTSD, have shown that these brain regions can over-or ...
14 hours ago | 5 / 5 (1) | 0 |
In 2008 researchers from the University of Southern Denmark showed that the drug thioridazine, which has previously been used to treat schizophrenia, is also a powerful weapon against antibiotic-resistant bacteria such as ...
23 hours ago | 3.7 / 5 (3) | 0 |